MBX Biosciences, Inc. has announced the pricing of an upsized public offering of 11,108,055 shares of its common stock at $18.00 per share, expecting gross proceeds of $199.9 million. The offering is expected to close on September 26, 2025, with underwriters having a 30-day option to purchase additional shares. J.P. Morgan, Jefferies, TD Cowen, and Guggenheim Securities are acting as joint book-running managers, with Citizens Capital Markets and Oppenheimer & Co. as co-lead managers. MBX Biosciences is focused on developing peptide therapies for endocrine and metabolic disorders based on its proprietary PEP™ platform.

This press release contains forward-looking statements from MBX Biosciences regarding the offering, subject to risks and uncertainties that may impact the company’s business. Factors affecting actual results include market conditions and closing conditions related to the offering. MBX Biosciences disclaims any obligation to update forward-looking statements. For more information, interested parties can contact Katie Beach Oltsik at [email protected] or Jim DeNike at [email protected].

Read more at GlobeNewswire: MBX Biosciences Announces Pricing of Upsized Public